AngioDynamics (ANGO) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AngioDynamics (ANGO) has outperformed Anbio Biotechnology (NNNN) over the past year, gaining 28.4% versus a loss of 83.4%. AngioDynamics is the larger company by market cap ($476.1 million vs $208.0 million), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANGO | NNNN |
|---|---|---|
| Share price | $11.32 | $4.74 |
| Market cap | $476.06M | $208.04M |
| 1-day change | -20.23% | -3.27% |
| YTD return | +10.51% | -83.70% |
| 1-year return | +28.42% | -83.37% |
| 5-year return | -48.15% | — |
| P/E ratio (TTM) | — | 31.60 |
| EPS (TTM) | $-0.88 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.29 | $44.73 |
| 52-week low | $9.39 | $4.66 |
| Distance from 52-week high | -30.51% | -89.40% |
| Analyst consensus | none | — |
| Avg. price target upside | +76.68% | — |
| Average volume | 514.11K | 147.21K |
| Shares outstanding | 42.05M | 43.89M |
| Employees | 632 | 27 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AngioDynamics is about 2.3 times larger than Anbio Biotechnology by market value ($476.06M vs $208.04M).
- ANGO has outperformed NNNN by 111.8 percentage points over the past year.
About AngioDynamics
ANGO stock →AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments.
Health Care · Medical/Dental Instruments · 632 employees
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
ANGO vs NNNN FAQ
Which is bigger, AngioDynamics or Anbio Biotechnology?
AngioDynamics (ANGO) is larger, with a market capitalization of $476.06M compared with $208.04M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, ANGO or NNNN?
ANGO returned +28.42% over the past 12 months, compared with -83.37% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are AngioDynamics and Anbio Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for AngioDynamics and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Anbio Biotechnology.